The first participants were treated in the study evaluating the effectiveness of the Magnus Neuromodulation System with SAINT Technology for MDD. Credit: Magnus Medical/Business Wire.

Magnus Medical has announced the treatment of the first participants in the Open-Label Optimisation (OLO) clinical trial of the SAINT neuromodulation system for major depression.

The study is intended to assess the effectiveness of the Magnus Neuromodulation System with SAINT Technology to treat major depressive disorder (MDD).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Leveraging structural and functional magnetic resonance imaging, the Magnus Neuromodulation System with SAINT Technology will inform an algorithm for identifying the optimal anatomic brain target for focused neurostimulation in individuals with MDD.

The trial will involve the participation of up to nine clinics across the US and enrol up to 1,000 adults with a major depressive episode who could not receive satisfactory improvement from previous antidepressant medication in the current episode.

The participants will receive the treatment on an accelerated schedule, with ten sessions a day, comprising ten-minute SAINT therapy treatments with breaks of 50 minutes for five consecutive days.

Magnus expects the results from the trial in 2027.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Magnus co-founder and chief scientific officer Dr Brandon Bentzley said: “Results from the previous randomised controlled trial were extremely promising – 79% of participants experienced relief from their severe depression after receiving SAINT treatment.

“Given the enormous need for acute care in depression, we knew we needed to make SAINT treatment more widely available while building a body of clinical data.”

The company secured breakthrough device designation from the US Food and Drug Administration for the Magnus Neuromodulation System with SAINT Technology for treatment-resistant depression.